Abstract |
Recainam hydrochloride is a newly synthesized propylurea compound demonstrating potent antidysrhythmic effects. Recainam was administered as a loading dose of 3 mg/kg/40 minutes followed by a continuous infusion of 0.9 mg/kg/hr for 23 hours and 20 minutes to ten patients with cardiac disease and frequent PVCs (more than 30/hr). A total of 15 plasma samples were drawn over 36 hours during and after the infusion. Plasma recainam concentration was determined by high performance liquid chromatography (HPLC). The mean (+/- SD) postload and 24-hour plasma concentrations were 5.19 +/- 0.51 and 3.41 +/- 0.71 micrograms/mL, respectively. The data were best described by a two-compartment model yielding the following mean (+/- SD) pharmacokinetic parameters: lambda 1 = 2.62 +/- 0.68 hr-1, lambda 2 = 0.144 +/- 0.014 hr-1, t1/2 lambda 2 = 4.84 +/- 0.46 hr, CLT = 0.268 +/- 0.057 L/hr/kg, CLR = 0.143 +/- 0.052 L/kg/hr, CLNR = 0.125 +/- 0.041 L/hr/kg, Vdss = 1.3 +/- 0.19 L/kg, and Vd lambda 2 = 1.9 +/- 0.43 L/kg. There were no adverse reactions. Based on these data, recainam can be safely administered as a loading dose followed by a continuous infusion in patients with stable cardiac disease without significant ventricular dysfunction.
|
Authors | E M Hampton, M I Anastasiou-Nana, J N Nanas, J M Nappi, D M Capuzzi, J L Anderson |
Journal | Journal of clinical pharmacology
(J Clin Pharmacol)
Vol. 27
Issue 12
Pg. 951-6
(Dec 1987)
ISSN: 0091-2700 [Print] England |
PMID | 3437067
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Arrhythmia Agents
- Phenylurea Compounds
- recainam
- Creatinine
|
Topics |
- Adult
- Aged
- Anti-Arrhythmia Agents
(administration & dosage, pharmacokinetics, therapeutic use)
- Cardiovascular Diseases
(drug therapy)
- Creatinine
(blood)
- Drug Evaluation
- Female
- Half-Life
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Phenylurea Compounds
(administration & dosage, pharmacokinetics, therapeutic use)
|